1. Show article details.

    ResMed Announces Participation in the Bank of America Merrill Lynch Global Healthcare Conference

    Business Wire – 9:00 AM ET 09/05/2019

    ResMed (RMD) today announced that Rob Douglas, president and chief operating officer, will present at the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, September 19, 2019, beginning at approximately 11:25 a.m. at the Bank of America Merrill Lynch Financial Centre in London.

  2. Show article details.

    ResMed Announces Participation in the 17th Annual Morgan Stanley Global Healthcare Conference

    Business Wire – 9:00 AM ET 08/26/2019

    ResMed (RMD) today announced that David Pendarvis, chief administrative officer and global general counsel, will participate in a fireside chat at the 17th Annual Morgan Stanley Global Healthcare Conference on Monday, September 9, 2019, beginning at approximately 2:50 p.m. at the Grand Hyatt New York in New York City.

  3. Show article details.

    Insulet Appoints Jim Hollingshead to Board of Directors

    Business Wire – 4:01 PM ET 07/31/2019

    Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that Jim Hollingshead, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately.

  4. Show article details.

    BRIEF-Resmed Inc. Q4 NON-GAAP Earnings Per Share $0.95

    Reuters – 4:51 PM ET 07/25/2019

    Resmed Inc (RMD): * . ANNOUNCES RESULTS FOR THE FOURTH QUARTER OF FISCAL YEAR 2019. * Q4 NON-GAAP EARNINGS PER SHARE $0.95. * Q4 GAAP EARNINGS PER SHARE $0.48. * Q4 REVENUE $705 MILLION VERSUS REFINITIV IBES ESTIMATE OF $702.3 MILLION. * Q4 EARNINGS PER SHARE ESTIMATE $0.94 -- REFINITIV IBES DATA. * QUARTERLY DIVIDEND INCREASED BY 5% TO $0.39 PER SHARE Source text for Eikon: Further company coverage:

  5. Show article details.

    ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2019

    Business Wire – 4:05 PM ET 07/25/2019

    Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO---- ResMed Inc. (RMD), a world-leading connected health company, today announced results for its quarter ended June 30, 2019.

  6. Show article details.

    60% of Referral Sources Would Switch to a Home Health and Hospice Provider that Accepts Electronic Referrals, Survey Reveals

    Business Wire – 10:20 AM ET 07/24/2019

    Survey also finds only 4% of home health and hospice organizations are able to accept electronic referrals from a referral source EMR system Brightree today announced results from the first-of-its-kind survey in post-acute care, revealing a significant gap between what referring providers and health systems want, and what home health and hospice providers are delivering, when it comes to intero...

  7. Show article details.

    MatrixCare Appoints Geriatrician Dheeraj Mahajan as Chief Medical Officer, Executive Vice President

    GlobeNewswire – 9:00 AM ET 07/16/2019

    MatrixCare announced today that Dheeraj Mahajan, MD, MBA, MPH, FACP, CMD, CIC, CHCQM, has joined its team as chief medical officer and executive vice president to advance MatrixCare’s vision of creating a seamless continuum where data moves with the patient, connecting both acute and post-acute care providers.

  8. Show article details.

    ResMed Inc. Completes $500M Private Placement Debt Offering

    Business Wire – 4:05 PM ET 07/15/2019

     . ResMed Inc. (RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering.

  9. Show article details.

    Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

    GlobeNewswire – 8:30 AM ET 07/15/2019

    Evolus (EOLS), Inc. , a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it has further strengthened and diversified its Board with the appointments of Peter Farrell, Ph.D. and Karah Parschauer, J.D. effective today.   “I am pleased to welcome Peter and Karah to the Evolus Board of Directors.

  10. Show article details.

    The S&P 500 just hit a record high -- so did these stocks

    MarketWatch – 6:52 AM ET 07/12/2019

    These 54 components of the S&P 500 rose to record levels too. Investors clearly find the U.S. stock market an attractive haven in a world of incredibly low interest rates. The S&P 500 Index hit an all-time intraday high on July 10, rising above 3,000 for the first time, before closing at 2,993.07, its second-highest close.

  11. Show article details.

    The Lancet Publishes: More Than 936 Million Have Obstructive Sleep Apnea Worldwide

    Business Wire – 6:30 PM ET 07/09/2019

    - Updated prevalence nearly 10 times greater than WHO’s 2007 estimate of more than 100 million - Untreated obstructive sleep apnea can lead to “major neurocognitive and cardiovascular” conditions, as well as high economic and societal costs, study says - ResMed-led analysis of data from 193 countries, using data from the World Health Organization, and United Nations World Population Prospects S...

  12. Show article details.

    ResMed to Report Fourth Quarter Fiscal 2019 Earnings on July 25, 2019

    Business Wire – 4:05 PM ET 07/03/2019

    ResMed (RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2019 on Thursday, July 25, 2019, after the New York Stock Exchange closes. Earnings webcast details: Please note that ResMed (RMD) does not use outside phone lines to access the earnings call.

  13. Show article details.

    Australian shares gain on U.S.-China ceasefire and RBA cut hopes; NZ flat

    Reuters – 10:01 PM ET 06/30/2019

    * Mining stocks boost the index. * Markets wait for possible RBA rate cut on Tuesday. * NZ flat after scaling record high earlier in session. By Ambar Warrick. Australian shares started the week higher as a U.S.-China trade ceasefire prompted risk-on buying, while the possibility of a local interest rate cut also lent support to equities.

Page:

Today's and Upcoming Events

  • Oct
    23

    RMD to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    14

    RMD ex-Dividend for $0.39 on 08/14/2019

    • Announce Date: 07/25/2019
    • Record Date: 08/15/2019
    • Pay Date: 09/19/2019
  • Jul
    25

    RMD announced Q4 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.